Skip to content

Randomized, double-blind, placebo-controlled clinical study of Huoxueiqiyang Qutan prescription in the treatment of hypertension with metabolic syndrome

Randomized, double-blind, placebo-controlled clinical study of Huoxueiqiyang Qutan prescription in the treatment of hypertension with metabolic syndrome

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081580
Enrollment
Unknown
Registered
2024-03-05
Start date
2023-07-08
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension with metabolic syndrome

Interventions

Treatment group:Western medicine basic treatment + Huoxue Qiyang Qutan prescription
Control group:Control group: Western medicine basic treatment + placebo

Sponsors

Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or inpatient patients with grade 1 or 2 essential hypertension who have taken or not taken antihypertensive drugs before and whose blood pressure is still between 140/90 and 179/109mmHg; 2. Age =18 years old and =80 years old, regardless of gender; 3. Meet the diagnostic criteria for metabolic syndrome in two or more of four categories: mid-abdominal obesity, hyperglycemia, elevated fasting triglycerides, and decreased fasting HDL; 4. In line with the diagnostic criteria of "excessive Yang - blood stasis - phlegm turbidness" syndrome of traditional Chinese medicine; 5. In the case of understanding the content of this study, voluntarily participate in and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant, or planning to become pregnant in the near future, or lactating women; 2. Serious heart, liver, kidney damage and other serious or even life-threatening diseases; 3. The subjects themselves could not cooperate due to alcoholism, intellectual disability and other reasons; 4. Patients with drug allergy in this study; 5. Have participated in or are participating in other clinical investigators within 3 months before enrollment; 6. History of myocardial infarction or obvious stroke in the past six months; 7. Other conditions deemed unsuitable for inclusion by other researchers.

Design outcomes

Primary

MeasureTime frame
Blood pressure;Cardiac ultrasound;

Secondary

MeasureTime frame
TCM symptom score;Physical index;Blood lipid;hs-CRP;IL-1ß;IL-6;IL-8;TNF-a;Trace albumin in urine;Urinary creatinine;Fasting blood glucose;Fasting insulin;adiponectin;

Countries

China

Contacts

Public ContactBo Lu

Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital

lubo200609@126.com+86 183 2186 6965

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026